Evaluation of an Assay for MGMT Gene Promoter Methylation in Glioblastoma Samples.
Anticancer Res
; 40(11): 6229-6236, 2020 Nov.
Article
em En
| MEDLINE
| ID: mdl-33109560
ABSTRACT
BACKGROUND/AIM:
To compare the GeneXpert® O6-methylguanine DNA methyltransferase (MGMT) methylation prototype (GX MGMT) assay with pyrosequencing in glioblastomas. MATERIALS ANDMETHODS:
The MGMT methylation status was retrospectively assessed in formalin-fixed paraffin embedded (FFPE) tumor blocks from 262 glioblastoma patients obtained from three independent cohorts using either a standard of care pyrosequencing laboratory developed test or the GX MGMT assay.RESULTS:
The concordance rate was 92.1% (58/63) for Oregon Health and Science University (OSHU) samples, 91.7% (88/96) for Medical University of Vienna (MUV) samples, and 82.5% (85/103) for Kepler University Hospital (KUH) samples. Patients with MGMT promoter hypermethylation assessed by pyrosequencing or the GX MGMT test had a significantly longer overall survival compared to patients without hypermethylation (HR=0.43, 95%CI=0.26-0.72, p=0.001 and HR=0.51, 95%CI=0.31-0.84, p=0.008, respectively).CONCLUSION:
Standardized, simplified, and on-demand testing of MGMT promoter methylation by the GX MGMT assay is feasible.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Bioensaio
/
Neoplasias Encefálicas
/
Metilases de Modificação do DNA
/
Reação em Cadeia da Polimerase
/
Regiões Promotoras Genéticas
/
Glioblastoma
/
Metilação de DNA
/
Proteínas Supressoras de Tumor
/
Enzimas Reparadoras do DNA
Tipo de estudo:
Evaluation_studies
Limite:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Child
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article